-Advertisement-

HomeLife SciencePharmaceuticals

Pharmaceuticals

Life Science

Bristol Myers Squibb Buys Mirati for $4.8B

Jeff Clemetson - October 16, 2023

Life Science

Arcturus Lands $9M for Inhaled mRNA CF Treatment

JENNIFER KASTNER - October 10, 2023

Life Science

Conduit Closes SPAC Merger

JEFF CLEMETSON - October 2, 2023

Pharmaceuticals

Ensysce Exploring Novel Pain Meds

JENNIFER KASTNER - September 20, 2023

Pharmaceuticals

Neurocrine Advances Pipeline of New, Existing Drugs

Jeff Clemetson - September 19, 2023

Life Science

Recludix Inks $1.3B Deal with Sanofi

Jeff Clemetson - July 31, 2023

Life Science

Gravity-Defying Drug Research

JENNIFER KASTNER - July 12, 2023

Life Science

Merck Closes Prometheus Acquisition

Jeff Clemetson - June 24, 2023

Life Science

Nielsen BioSciences Inks $100M Deal

Jeff Clemetson - May 27, 2023

Life Science

SD Startup Targets Dupuytren’s Disease Treatment

JENNIFER KASTNER - May 17, 2023

Life Science

Bayer to Make U.S. Drug Development a ‘Cornerstone’

Jeff Clemetson - May 8, 2023

Life Science

FDA OK’s New ALS Drug

Jeff Clemetson - May 7, 2023

Life Science

Biotheryx Inks Collaboration Deal with Incyte

Jeff Clemetson - April 19, 2023

Life Science

Trio Pharmaceuticals Raises $2.2 Million Seed

Jeff Clemetson - April 11, 2023

Life Science

FDA Approves Cidara’s Antifungal Therapy

Jeff Clemetson - April 7, 2023

Life Science

FDA OKs Acadia’s Rett Syndrome Drug

Jeff Clemetson - March 27, 2023

Life Science

Gates MRI Licenses Calibr Tuberculosis Treatment Discovery

Jeff Clemetson - March 10, 2023

Life Science

Capricor Inks $100M Deal with Nippon Shinyaku

Jeff Clemetson - March 1, 2023

Life Science

Resilience Tapped to Operate Biopharma Facility in UAE

JEFF CLEMETSON - February 3, 2023

enews

Toragen Explores ‘Novel’ Treatment for HPV-Induced Cancer

Jeff Clemetson - December 14, 2022

-Advertisment-

-Advertisement-

Pharmaceuticals

Bristol Myers Squibb Buys Mirati for $4.8B

Arcturus Lands $9M for Inhaled mRNA CF Treatment

Conduit Closes SPAC Merger

Ensysce Exploring Novel Pain Meds

Neurocrine Advances Pipeline of New, Existing Drugs

Recludix Inks $1.3B Deal with Sanofi

Gravity-Defying Drug Research

Merck Closes Prometheus Acquisition

Nielsen BioSciences Inks $100M Deal

SD Startup Targets Dupuytren’s Disease Treatment

Bayer to Make U.S. Drug Development a ‘Cornerstone’

FDA OK’s New ALS Drug

Biotheryx Inks Collaboration Deal with Incyte

Trio Pharmaceuticals Raises $2.2 Million Seed

FDA Approves Cidara’s Antifungal Therapy

FDA OKs Acadia’s Rett Syndrome Drug

Gates MRI Licenses Calibr Tuberculosis Treatment Discovery

Capricor Inks $100M Deal with Nippon Shinyaku

Resilience Tapped to Operate Biopharma Facility in UAE

Toragen Explores ‘Novel’ Treatment for HPV-Induced Cancer

Browse More

Learn More

Services

Other Journals